Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from RAPT Therapeutics ( (RAPT) ).
On March 3, 2026, RAPT Therapeutics completed a merger under Delaware law that did not require a shareholder vote, resulting in all validly tendered shares being accepted for payment and the company becoming a direct wholly owned subsidiary of the acquiring parent. In connection with the closing, RAPT notified Nasdaq of the transaction, requested the halt and delisting of its shares and subsequent deregistration with the SEC, and implemented sweeping governance changes, including the resignation of the prior board, replacement of all incumbent officers with executives from the purchaser, and the adoption of amended and restated charter documents, effectively transitioning RAPT from a publicly traded entity to a privately held subsidiary under new control.
The most recent analyst rating on (RAPT) stock is a Hold with a $58.00 price target. To see the full list of analyst forecasts on RAPT Therapeutics stock, see the RAPT Stock Forecast page.
Spark’s Take on RAPT Stock
According to Spark, TipRanks’ AI Analyst, RAPT is a Neutral.
The score is held back primarily by weak financial performance (no revenue, large losses, and heavy cash burn). Offsetting that, the stock shows strong upward technical momentum and, most importantly, a definitive cash acquisition agreement at $58/share materially supports the near-term investment profile despite remaining deal-closure conditions.
To see Spark’s full report on RAPT stock, click here.
More about RAPT Therapeutics
RAPT Therapeutics operates in the biopharmaceutical industry, historically focusing on the discovery and development of oral small molecule therapies targeting immune and inflammatory diseases and cancer. The company’s shares were previously listed on Nasdaq, giving it access to public equity markets and a broad base of institutional and retail investors.
Average Trading Volume: 2,649,246
Technical Sentiment Signal: Buy
Current Market Cap: $1.61B
For a thorough assessment of RAPT stock, go to TipRanks’ Stock Analysis page.